300+ investors in your industry, stage, and region Get
Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Mobile
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Film
Oil and Gas
Retail
Payments
Organic Food
Marketplace
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Social Network
B2B
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Software
Blockchain
Theatre
Medical
Web3
Beauty
Recruiting
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
Fashion
Infrastructure
Social
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
Faroe Islands
United Kingdom
Oceania
South Korea
Argentina
Tunisia
Taiwan
Zimbabwe
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Oman
Poland
Puerto Rico
Guernsey
Cameroon
China
Colombia
Armenia
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Luxembourg
Marshall Islands
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Morocco
Uzbekistan
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
New Zealand
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
Seychelles
Paraguay
South Africa
Botswana
France
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
Germany
India
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Middle East
Indonesia
Dominican Republic
Bermuda
Albania
Asia
Spain
Bangladesh
Barbados
Belgium
Angola
Austria
Europe
Ethiopia
Jordan
Cyprus
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Qatar
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Liechtenstein
Cambodia
Iceland
Lebanon
Slovenia
Mongolia
Peru
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Ascenta Capital, VC Fund

Ascenta Capital

VC Fund

New York, United States

Ascenta Capital is a private equity and venture capital firm.

Total investments:
12
Last investment:
Lead investor:
75%
Fund size:
$325M
Last fund:

Last updated:

Industries Ascenta Capital invests in

BiotechnologyHealth CareMedicalPharmaceuticalBiopharma

Stages Ascenta Capital invests in

Series BSeries CFunding Round

Countries Ascenta Capital invests in

United StatesCanadaGermany

Contacts

NameEmailPhoneSocials

Sign up to unlock verified contacts

Unlock Contacts

Investment Focus

Industry

  • Biotechnology 7 (58%)
  • Health Care 5 (42%)
  • Medical 4 (33%)
  • Pharmaceutical 3 (25%)
  • Biopharma 2 (17%)
See all 11 industries →

Stage

  • Series B 5 (42%)
  • Series C 5 (42%)
  • Funding Round 1 (8%)

Country

  • United States 7 (58%)
  • Canada 1 (8%)
  • Germany 1 (8%)

Team

NameTitleInvestmentsLinksEmail
Lorence Kim
Lorence Kim Co-founder and Managing Partner
Co-founder and Managing Partner Total investments: 5
Find email

Investments

CompanyDescriptionRoundLinks
Triveni Bio is at the forefront of human genetics, cutting-edge antibody design, and precision medicine, pioneering the identification of new disease targets. $65M / Series C / Jun 17, 2026
Triana Biomedicines Triana Biomedicines
Triana Biomedicines is building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high- resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas. $120M / Series B / Dec 03, 2025
The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant, a multi-modal transformer model that predicts clinical outcomes from the earliest stages of discovery, and NeuralPLexer, the best-in-class predictor of protein and protein-ligand structures.The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multi-parameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated experimental execution, Iambic completes design-make-test cycles on a weekly cadence. $127.8M / Nov 10, 2025
Tubulis is a biotechnology company that develops antibody-drug conjugates (ADCs) for targeted cancer therapy. The company combines proprietary technologies with disease-specific biological insights to create highly stable and effective protein-drug conjugates. Its platform enables the design of ADCs with improved delivery, reduced toxicity, andenhanced therapeutic potential across various cancer types, including solid and hematologic tumors. Tubulis is advancing a pipeline of experimental drug candidates, such as TUB-040 and TUB-030, which are currently being evaluated in clinical settings for cancers like ovarian and lung cancer. The company also collaborates with industry partners and leverages its proprietary conjugation technologies to expand the scope and effectiveness of targeted oncology treatments. $400.6M / Series C / Oct 15, 2025
Alpha9 Theranostics is a clinical-stage biopharmaceutical company. $175M / Series C / Oct 23, 2024
OrsoBio is a clinical-stage biopharmaceutical company that creates therapies for patients suffering from severe metabolic disorders such as diabetes, severe dyslipidemia, lipodystrophies, and others. OrsoBio is committed to restoring energy homeostasis in patients with severe metabolic disorders, in some cases, by targeting pathways relevant tomaintaining energy balance. OrsoBio revolutionizes the treatment of these disorders by addressing the underlying cause. $67M / Series B / Sep 06, 2024
Cardurion Pharmaceuticals is a Boston-based biotechnology company focused on developing novel therapeutics for the treatment of heart failure and other cardiovascular diseases. The company is advancing groundbreaking clinical programs targeting PDE9 and CaMKII inhibition, leveraging its expertise in cardiovascular signaling pathways to addressunmet patient needs. $260M / Series B / Jul 16, 2024
Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines. $101M / Series C / Dec 05, 2023
The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant, a multi-modal transformer model that predicts clinical outcomes from the earliest stages of discovery, and NeuralPLexer, the best-in-class predictor of protein and protein-ligand structures.The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multi-parameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated experimental execution, Iambic completes design-make-test cycles on a weekly cadence. $100M / Series B / Oct 03, 2023
ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts. It discovers and develops innovative therapeutics that can utilize a family of endogenous enzymes called adenosine deaminase acting on RNA (ADAR) to precise target and correct single point mutations on an mRNA, thus the production of desired andfunctional protein is restored. It was founded in 2019 and is headquartered in San Diego, California. $200M / Series C / Aug 09, 2023
See all 12 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Mobile
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Film
Oil and Gas
Retail
Payments
Organic Food
Marketplace
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Social Network
B2B
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Software
Blockchain
Theatre
Medical
Web3
Beauty
Recruiting
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
Fashion
Infrastructure
Social
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
Faroe Islands
United Kingdom
Oceania
South Korea
Argentina
Tunisia
Taiwan
Zimbabwe
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Oman
Poland
Puerto Rico
Guernsey
Cameroon
China
Colombia
Armenia
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Luxembourg
Marshall Islands
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Morocco
Uzbekistan
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
New Zealand
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
Seychelles
Paraguay
South Africa
Botswana
France
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
Germany
India
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Middle East
Indonesia
Dominican Republic
Bermuda
Albania
Asia
Spain
Bangladesh
Barbados
Belgium
Angola
Austria
Europe
Ethiopia
Jordan
Cyprus
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Qatar
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Liechtenstein
Cambodia
Iceland
Lebanon
Slovenia
Mongolia
Peru
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Ascenta Capital invest in?

Ascenta Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series C stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact Ascenta Capital?

Public channels for Ascenta Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Ascenta Capital?

The team at Ascenta Capital includes Lorence Kim (Co-founder and Managing Partner). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Ascenta Capital Ascenta Capital Find emails